SCHEMBL6777437

SCHEMBL6777437

Cc1ccc(C(=O)NCC(=O)NC(CC(=O)O)c2cccnc2)cc1N

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITGB3 P05106 8/20 0.51
ITGA2B P08514 4/20 0.51
SUCNR1 Q9BXA5 2/20 0.49
ITGB1 P05556 4/20 0.43
ITGAV P06756 4/20 0.43
ITGA5 P08648 4/20 0.43
ITGB5 P18084 3/20 0.43
ITGB6 P18564 3/20 0.43
ITGB8 P26012 3/20 0.43
ITGA8 P53708 3/20 0.43
ROCK2 O75116 1/20 0.42
ROCK1 Q13464 1/20 0.42
SLC6A9 P48067 3/20 0.42
GPR139 Q6DWJ6 2/20 0.42
MAPT P10636 2/20 0.41
TP53 P04637 1/20 0.41
TAOK1 Q7L7X3 1/20 0.40
TAOK3 Q9H2K8 1/20 0.40
MDM4 O15151 1/20 0.40
MDM2 Q00987 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6779902 0.86 ITGB3 (0.56) ITGB3ITGA2BSUCNR1ITGB1ITGAV
SCHEMBL7336878 0.85 SUCNR1 (0.47) ITGB3ITGA2BSUCNR1ITGB1ITGAV
SCHEMBL6780209 0.80 ITGB3 (0.55) ITGB3ITGA2BSUCNR1ITGB1ITGAV
SCHEMBL29391928 0.80 ITGB3 (0.55) ITGB3ITGA2BSUCNR1ITGB1ITGAV
SCHEMBL30184664 0.79 ITGB3 (0.65) ITGB3ITGA2BSUCNR1ITGB1ITGAV
SCHEMBL6773340 0.79 ITGB3 (0.53) ITGB3ITGA2BSUCNR1ITGB1ITGAV
SCHEMBL6776653 0.79 ITGB3 (0.58) ITGB3ITGA2BSUCNR1ITGB1ITGAV
SCHEMBL6778483 0.78 SUCNR1 (0.53) ITGB3ITGA2BSUCNR1ITGB1ITGAV
SCHEMBL6777910 0.78 ITGB3 (0.52) ITGB3ITGA2BSUCNR1ITGB1ITGAV
SCHEMBL7343426 0.78 SUCNR1 (0.53) ITGB3ITGA2BSUCNR1ITGB1ITGAV

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6831199-B1 In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 G. D. SEARLE & CO. 2004-12-14 US disclosed
EP-0850221-B1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS SEARLE & CO (US) 2001-07-18 EP disclosed
US-6028223-A AN INTEGRIN ANTAGONISTS TREATING BONE DISORDER, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR ANGIOGENESIS, DIABETIC RETINOPATHY, ARTHRITIS, SMOOTH MUSCLE CELL MIGRATION AND RESTENOSIS G. D. SEARLE & CO. (US) 2000-02-22 US disclosed
EP-0850221-A1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1998-07-01 EP disclosed
WO-1997008145-A1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1997-03-06 WO disclosed